TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
Soo, Ross Andrew, de Marinis, Filippo, Han, Ji-Youn, Ho, James Chung-Man, Martin, Emma, Servidio, Leslie, Sandelin, Martin, Popat, Sanjay
Published in Clinical lung cancer (01.01.2024)
Published in Clinical lung cancer (01.01.2024)
Get full text
Journal Article
Treatment patterns and outcomes in resectable early stage NSCLC: Interim analysis of a global real-world study
Lin, Steven H., Ahn, Myung-Ju, Nagar, Saurabh P., Affi, Raafet, Agulnik, Jason, Shih, Jin-Yuan, Hochmair, Maximilian J., Tufman, Amanda, Debieuvre, Didier, Jimenez, Maria, Davis, Keith, Kahangire, Doreen A., Servidio, Leslie Ann, Veluswamy, Rajwanth
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
Cheema, Parneet, Cho, Byoung Chul, Freitas, Helano, Provencio, Mariano, Chen, Yuh Min, Kim, Sang-We, Wu, Yi-Long, Passaro, Antonio, Martin, Claudio, Tiseo, Marcello, Chang, Gee-Chen, Park, Keunchil, Solomon, Benjamin, Burghuber, Otto, Laskin, Janessa, Wang, Ziping, Lee, Sung Yong, Hu, Yanping, Vansteenkiste, Johan, Zhang, He-Long, Hanrahan, Emer, Geldart, Thomas, Taylor, Rosemary, Servidio, Leslie, Li, Jingyi, Marinis, Filippo de
Published in Future oncology (London, England) (01.01.2023)
Published in Future oncology (London, England) (01.01.2023)
Get full text
Journal Article